Bivalirudin: an anticoagulant option for percutaneous coronary intervention (Q28168650)

Expert Review of Cardiovascular Therapy

Europe PubMed Central

title

Bivalirudin: an anticoagulant option for percutaneous coronary intervention (English)

0 references

1 reference

1 reference

Eric R Bates

1

0 references

language of work or name

English

0 references

publication date

March 2004

0 references

published in

0 references

volume

2

0 references

issue

2

0 references

page(s)

153-62

0 references

cites work

ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction--2002: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice G

1 reference

https://api.crossref.org/works/10.1586/14779072.2.2.153

Direct thrombin inhibitors in cardiac disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.2.153

Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.2.153

Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.2.153

Platelets and thrombin generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.2.153

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.2.153

Thrombin signalling and protease-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.2.153

Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.2.153

Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.2.153

Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.2.153

Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.2.153

Should bivalirudin replace heparin during percutaneous coronary interventions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.2.153

Periprocedural myocardial infarction and mortality: causality versus association

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.2.153

Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.2.153

The SYNERGY trial: study design and rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.2.153